{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:48:47Z","timestamp":1777294127937,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06462-3","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T01:42:42Z","timestamp":1750642962000},"page":"3855-3861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center"],"prefix":"10.1007","volume":"104","author":[{"given":"Sabrina","family":"Giammarco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Metafuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Assunta","family":"Limongiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Sor\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Frioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Di Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"12","key":"6462_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"key":"6462_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"issue":"8","key":"6462_CR3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","volume":"117","author":"V Gupta","year":"2011","unstructured":"Gupta V, Tallman MS, Weisdorf DJ (2011) Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117(8):2307\u20132318","journal-title":"Blood"},{"issue":"8","key":"6462_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS et al (2015) Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033\u20131040","journal-title":"Blood"},{"issue":"26","key":"6462_CR5","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36(26):2684\u20132692","journal-title":"J Clin Oncol"},{"key":"6462_CR6","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE et al (2014) Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/ daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood 123:3239\u20133246","journal-title":"Blood"},{"issue":"7","key":"6462_CR7","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK et al (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and Daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8(7):e481\u2013e491","journal-title":"Lancet Haematol"},{"key":"6462_CR8","doi-asserted-by":"publisher","first-page":"e1414","DOI":"10.1634\/theoncologist.2019-0785","volume":"25","author":"K Tzogani","year":"2020","unstructured":"Tzogani K, Penttil\u00e4 K, Lapvetel\u00e4inen T, Hemmings R, Koenig J, Freire J et al (2020) EMA review of Daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, Therapy-Related acute myeloid leukemia or acute myeloid leukemia with Myelodysplasia-Related changes. Oncologist 25:e1414\u2013e1420","journal-title":"Oncologist"},{"key":"6462_CR9","doi-asserted-by":"crossref","unstructured":"Galloway-Pe\u00f1a JR, Yushu Shi, Peterson CB, Pranoti Sahasrabhojane, Vancheswaran Gopalakrishnan, Brumlow CE et al (2020) Gut Microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin Infect Dis 71(1):63\u201371","DOI":"10.1093\/cid\/ciz777"},{"issue":"11","key":"6462_CR10","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1182\/bloodadvances.2021006783","volume":"6","author":"A Rashidi","year":"2022","unstructured":"Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Halaweish HF, Kaiser T et al (2022) Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Adv 6(11):3451\u20133457","journal-title":"Blood Adv"},{"issue":"16","key":"6462_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood.2023021380","volume":"143","author":"G Renga","year":"2024","unstructured":"Renga G, Nunzi E, Stincardini C, Pariano M, Puccetti M, Pieraccini G et al (2024) CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance and immune homeostasis. Blood 143(16):1628\u20131645","journal-title":"Blood"},{"key":"6462_CR12","doi-asserted-by":"crossref","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U et al (2016) International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl 22(1):4\u201310","DOI":"10.1016\/j.bbmt.2015.09.001"},{"issue":"8","key":"6462_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic. Cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919","journal-title":"Blood"},{"issue":"4","key":"6462_CR14","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.beha.2021.101335","volume":"34","author":"JM Foran","year":"2021","unstructured":"Foran JM (2021) Can venetoclax-based therapy replace 7\u2009+\u20093 induction in fit older adults with AML? Best Pract Res Clin Haematol 34(4):101335","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"6462_CR15","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","volume":"130","author":"AH Wei","year":"2017","unstructured":"Wei AH, Tiong IS (2017) Midostaurin, enasidenib, CPX-351, Gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130(23):2469\u20132474","journal-title":"Blood"},{"issue":"1","key":"6462_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","volume":"21","author":"P Vyas","year":"2015","unstructured":"Vyas P, Appelbaum FR, Craddock C (2015) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transpl 21(1):8\u201315","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"6462_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00432-021-03733-0","volume":"148","author":"M Fleischmann","year":"2022","unstructured":"Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J et al (2022) Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. J Cancer Res Clin Oncol 148(6):1481\u20131492","journal-title":"J Cancer Res Clin Oncol"},{"issue":"19","key":"6462_CR18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1200\/JCO.19.03306","volume":"38","author":"TM Cooper","year":"2020","unstructured":"Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA et al (2020) Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and Granulocyte-Colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children\u2019s oncology group. J Clin Oncol 38(19):2170\u20132177","journal-title":"J Clin Oncol"},{"issue":"7","key":"6462_CR19","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","volume":"5","author":"LD Mayer","year":"2006","unstructured":"Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA et al (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5(7):1854\u20131863","journal-title":"Mol Cancer Ther"},{"key":"6462_CR20","doi-asserted-by":"crossref","unstructured":"Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT et al (2012) Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res 36:1283\u20131289","DOI":"10.1016\/j.leukres.2012.07.006"},{"key":"6462_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","volume":"29","author":"EJ Feldman","year":"2011","unstructured":"Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF et al (2011) First-in-man study of CPX-351: A liposomal carrier containing cytarabine and Daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29:979\u2013985","journal-title":"J Clin Oncol"},{"key":"6462_CR22","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD et al (2010) Leukemia-selective uptake and cytotoxicity of CPX351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 34:1214\u20131223","journal-title":"Leuk Res"},{"issue":"1","key":"6462_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, Rahm\u00b4e R, Bertoli S, Dumas PY, Micol JB, Hicheri Y et al (2021) Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv 5(1):176\u2013184","journal-title":"Blood Adv"},{"issue":"10","key":"6462_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","volume":"10","author":"F Guolo","year":"2020","unstructured":"Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S et al (2020) CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J 10(10):96","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"6462_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/blood-2021-153791","volume":"138","author":"A Przespolewski","year":"2021","unstructured":"Przespolewski A, Goldberg AD, Talati C, Fazal S, Vachhani P, Sanikommu SRR (2021) Safety and efficacy of CPX-351 in younger patients\u2009<\u200960 years old with secondary acute myeloid leukemia: an updated analysis. Blood 138(Suppl 1):1264","journal-title":"Blood"},{"issue":"10","key":"6462_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","volume":"11","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C, Stolzel\u00a8F, Rollig\u00a8C, Stelljes M, Gaidzik V, Lauseker M et al (2021) Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J 11(10):164","journal-title":"Blood Cancer J"},{"key":"6462_CR27","doi-asserted-by":"crossref","unstructured":"Murthy V, Whitmill R, Lodwick C, Dyer P, Ahmed M, Khan R et al (2021) CPX-351 for acute myeloid leukaemia: real world results are comparable to trial outcomes and exceeds them in non-adverse risk patients - a multicentre experience from West Midlands hospitals on behalf of West Midlands Research Consortium (WMRC) UK. Blood 138 (Suppl 1):4416","DOI":"10.1182\/blood-2021-150199"},{"issue":"Suppl 1","key":"6462_CR28","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2021-153028","volume":"138","author":"P Minetto","year":"2021","unstructured":"Minetto P, Guolo F, Fianchi L, Clavio M, Gottardi M, Endri M et al (2021) CPX-351 induction in secondary acute myeloblastic leukemia: extended follow up from the Italian compassionate use program. Blood 138(Suppl 1):1262","journal-title":"Blood"},{"key":"6462_CR29","doi-asserted-by":"publisher","first-page":"103984","DOI":"10.1016\/j.critrevonc.2023.103984","volume":"May","author":"RM Lemoli","year":"2023","unstructured":"Lemoli RM, Montesinos P (2023) Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Crit Rev Oncol Hematol May:185:103984","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6462_CR30","doi-asserted-by":"publisher","first-page":"1800897","DOI":"10.1080\/19490976.2020.1800897","volume":"12","author":"T Hueso","year":"2020","unstructured":"Hueso T, Ekpe K, Mayeur C, Gatse A, Joncquel-Chevallier Curt M, Gricourt G et al (2020) Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening. Gut Microbes 12(1):1800897","journal-title":"Gut Microbes"},{"key":"6462_CR31","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3389\/fonc.2020.01746","volume":"10","author":"V Vucinic","year":"2020","unstructured":"Vucinic V, Jentzsch M, Schwind S, Bach E, Leiblein S, Remane Y et al (2020) Case report: allogeneic stem cell transplantation following induction with CPX-351 in patients with acute myeloid leukemia is feasible. Front Oncol 10:1746","journal-title":"Front Oncol"},{"key":"6462_CR32","doi-asserted-by":"publisher","first-page":"1272072","DOI":"10.3389\/fonc.2023.1272072","volume":"13","author":"E Benedetti","year":"2023","unstructured":"Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Lippolis P et al (2023) Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients. Front Oncol 13:1272072","journal-title":"Front Oncol"},{"issue":"10","key":"6462_CR33","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/j.clml.2023.07.003","volume":"23","author":"A Legg","year":"2023","unstructured":"Legg A, Lambova A, Broe A, Levy J, Medalla G (2023) Real-World experience with CPX-351 treatment for acute myeloid leukemia in england: an analysis from the National Cancer registration and analysis service. Clin Lymphoma Myeloma Leuk 23(10):e323\u2013e330","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"6462_CR34","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/cancers16050915","volume":"16","author":"SR Solomon","year":"2024","unstructured":"Solomon SR, Powell BL, Koprivnikar J, Lai C, Male H, Michaelis LC et al (2024) CPX-351 pharmacokinetics and safety in adults with hematologic malignancies and renal function impairment: phase 1 trial. Cancers (Basel) 16(5):915","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6462_CR35","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/microorganisms11092182","volume":"11","author":"E Metafuni","year":"2023","unstructured":"Metafuni E, Di Marino L, Giammarco S, Bellesi S, Limongiello MA, Sor\u00e0 F et al (2023) The role of fecal microbiota transplantation in the allogeneic stem cell transplant setting. Microorganisms 11(9):2182","journal-title":"Microorganisms"},{"key":"6462_CR36","doi-asserted-by":"crossref","unstructured":"Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ et al (2022) Transplant outcomes after CPX-351 vs 7\u2009+\u20093 in older adults with newly diagnosed high-risk and\/or secondary AML. Blood Adv. 2022;6(17):4989\u20134993. Erratum in: Blood Adv. 2023;7(12):2715\u20132717","DOI":"10.1182\/bloodadvances.2023010005"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06462-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:37:21Z","timestamp":1757194641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06462-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6462"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06462-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}